ASDS 2024: Phase III READY-4 Data Show Long-Term Safety and Efficacy of Galderma’s Relfydess™

Galderma has announced new Phase III data from the READY-4 clinical trial, showcasing the long-term safety and efficacy of RelabotulinumtoxinA (Relfydess™) for treating frown lines and crow’s feet after repeated injections. The study met its primary and secondary endpoints, revealing…









